We found that Neuropilin-1 (NRP1), a receptor constitutively expressed by thymically- derived regulatory T cells (Tregs) and crucial for their suppression of anti-tumor immunity [2], is transiently induced in effector CD8+ T cells in mouse tumor models and in patients with advanced head and neck cancer.We are interested in understanding the impact of CD8+ T cell-expressing NRP1 on both the short- and long-term tumor surveillance and the implication in cancer immunotherapy. The gene discussed is CD8A; the disease is cancer.